AstraZeneca (LSE:AZN) has seen a shift recently with the EU approval of ENHERTU® and Imfinzi®, which are likely influential ...

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

The EC based its decision on data from the DESTINY-Breast06 trial, which included patients whose tumors had very low levels of HER2 expression.

The European Commission (EC) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for use as a ...

Enhertu gains EU approval for treating advanced breast cancer with low HER2 levels, marking a milestone for Daiichi Sankyo & ...

AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the European Commission (EC) to ...

Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

Daiichi Sankyo (DSNKY) and AstraZeneca’s Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hor ...

The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...

LUND, SE / ACCESS Newswire / April 4, 2025 / BioInvent International AB ("BioInvent") , a biotech company focused on the discovery and development of novel and first-in-class immunomodulatory ...

In early corporate news, BP Chair Helge Lund announced his intention to resign, and AstraZeneca received EU approval for two different therapies. Here is what you need to know at the London market ...

AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...